Nicola Staff asked 1 month ago
You have seen the truth of things here, that this chemical substance has an important drawback heretofore not fully appreciated. This is not at all uncommon when new drugs are devised for chronic illnesses ravaging the body with a number of physiologic and biochemical derangements. The drugs, or their metabolic end products, may well produce negative effects that compound the damage of ongoing pathologic illness, and this creates a particularly insidious circumstance where it may well be missed, at least at first, so that only after a long period of being on the market will it finally be appreciated that it actually can worsen some aspects of the disease it is designed to treat. Metformin inherently is nephrotoxic, so it will be a function of time, dose level, and the individual makeup of each patient as to whether there will be a visible and measurable consequence, due to the large kidney reserve capacity except when there is well entrenched chronic kidney disease, so a further liability, like adding a drug like metformin, might not be suspected as a culprit. But far too often, people with Type 2 diabetes are put on the drug before there is enough kidney damage to be detectable, and when kidney problems develop it is just assumed to be an advancement of the diabetes and, if anything, the dose of metformin will be increased to combat it and thus contribute to a downward spiral.
Please login or Register to submit your answer
